β-Lactamases are bacterial enzymes conferring resistance to β-lactam antibiotics in clinically-relevant pathogens, and represent relevant drug targets. Recently, the identification of new boronic acids (i.e. RPX7009) paved the way to the clinical application of these molecules as potential drugs. Here, we screened in silico a library of ~1400 boronic acids as potential AmpC β-lactamase inhibitors. Six of the most promising candidates were evaluated in biochemical assays leading to the identification of potent inhibitors of clinically-relevant β-lactamases like AmpC, KPC-2 and CTX-M-15. One of the selected compounds showed nanomolar Ki value with the clinically-relevant KPC-2 carbapenemase, while another one exhibited broad spectrum inhibition, being also active on Enterobacter AmpC and the OXA-48 class D carbapenemase.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors|
|Rivista:||JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN|
|Citazione:||Sgrignani, J., DE LUCA, F., Torosyan, H., Docquier, J.D., Duan, D.a., Novati, B., et al. (2016). Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 30(10), 851-861.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: